JP4896333B2 - 薬理活性抗ウイルスペプチドおよびそれらの使用法 - Google Patents

薬理活性抗ウイルスペプチドおよびそれらの使用法 Download PDF

Info

Publication number
JP4896333B2
JP4896333B2 JP2001557903A JP2001557903A JP4896333B2 JP 4896333 B2 JP4896333 B2 JP 4896333B2 JP 2001557903 A JP2001557903 A JP 2001557903A JP 2001557903 A JP2001557903 A JP 2001557903A JP 4896333 B2 JP4896333 B2 JP 4896333B2
Authority
JP
Japan
Prior art keywords
peptide
antiviral
virus
peptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001557903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522185A5 (enExample
JP2003522185A (ja
Inventor
ブラント，カーテイス
ブルトマン，ヘルマン
Original Assignee
ウイスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウイスコンシン アラムニ リサーチ ファンデーション filed Critical ウイスコンシン アラムニ リサーチ ファンデーション
Publication of JP2003522185A publication Critical patent/JP2003522185A/ja
Publication of JP2003522185A5 publication Critical patent/JP2003522185A5/ja
Application granted granted Critical
Publication of JP4896333B2 publication Critical patent/JP4896333B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2001557903A 2000-02-07 2001-02-06 薬理活性抗ウイルスペプチドおよびそれらの使用法 Expired - Fee Related JP4896333B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18082300P 2000-02-07 2000-02-07
US60/180,823 2000-02-07
US18405700P 2000-02-22 2000-02-22
US60/184,057 2000-02-22
PCT/US2001/003813 WO2001057072A2 (en) 2000-02-07 2001-02-06 Pharmacologically active antiviral peptides and methods of their use

Publications (3)

Publication Number Publication Date
JP2003522185A JP2003522185A (ja) 2003-07-22
JP2003522185A5 JP2003522185A5 (enExample) 2011-04-21
JP4896333B2 true JP4896333B2 (ja) 2012-03-14

Family

ID=26876670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001557903A Expired - Fee Related JP4896333B2 (ja) 2000-02-07 2001-02-06 薬理活性抗ウイルスペプチドおよびそれらの使用法

Country Status (9)

Country Link
US (3) US7371809B2 (enExample)
EP (1) EP1272510B1 (enExample)
JP (1) JP4896333B2 (enExample)
AT (1) ATE374208T1 (enExample)
AU (1) AU784264B2 (enExample)
CA (1) CA2399676C (enExample)
DE (1) DE60130641T2 (enExample)
ES (1) ES2293977T3 (enExample)
WO (1) WO2001057072A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272510B1 (en) 2000-02-07 2007-09-26 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
US7094413B2 (en) * 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
US7432045B2 (en) 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides
JP4831410B2 (ja) 2006-02-28 2011-12-07 東亞合成株式会社 抗ウイルス性ペプチドおよび抗ウイルス剤
CA2727898A1 (en) 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel antiviral peptides against influenza virus
WO2009152518A1 (en) * 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel peptide adjuvant for influenza vaccination
AU2009292959B2 (en) * 2008-09-19 2016-02-25 Henry Ford Health System Methods, systems, and compositions for calpain inhibition
GB201012651D0 (en) * 2010-07-28 2010-09-15 Univ Edinburgh Peptides
WO2012071549A2 (en) 2010-11-24 2012-05-31 Clontech Laboratories, Inc. Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
US20120190107A1 (en) * 2011-01-26 2012-07-26 Dwayne Bisgrove Enhanced protein transduction
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético
KR20200012894A (ko) 2017-05-26 2020-02-05 비라매틱스 에스디엔 비에이치디 펩타이드 및 항바이러스제로서의 이의 용도
KR20240067073A (ko) * 2021-08-23 2024-05-16 아미트렉스 테라퓨틱스, 인크. 백혈구 특이적 세포 투과 분자

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795740A (en) * 1986-05-20 1989-01-03 Cohen Eric A Antiviral peptides and means for treating herpes infections
US4814432A (en) 1987-05-22 1989-03-21 Merck & Co., Inc. Inhibitor of ribonucleotide reductase
US5260420A (en) * 1987-07-30 1993-11-09 Centre Regional De Transfusion Sanguine De Lille Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
US5104854A (en) * 1989-02-01 1992-04-14 Washington University Antiviral peptides
CA1340682C (en) * 1989-07-07 1999-07-27 Pierre Lavallee Antiviral peptides having a 2-oxoalkyl amino acid side chain
IT1231342B (it) * 1989-08-28 1991-11-28 Prodotti Antibiotici Spa Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono
JPH0421635A (ja) 1990-05-16 1992-01-24 Suntory Ltd アセトアルデヒドの毒性抑制剤およびアセトアルデヒドの毒性抑制に有効な飲食物
CA2033447C (en) * 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
EP0531080A3 (en) 1991-09-04 1993-12-29 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein
EP0726749B1 (en) * 1993-11-03 2004-08-11 Clarion Pharmaceuticals, Inc. Hemostatic patch
US5441936A (en) * 1993-12-07 1995-08-15 Houghten Pharmaceuticals, Inc. Antiviral peptides
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
AU3982497A (en) 1996-07-30 1998-02-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in controlled manner
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
AU6972798A (en) * 1997-04-18 1998-11-13 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
FR2766826B1 (fr) * 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
WO1999064449A2 (en) * 1998-06-10 1999-12-16 The Queen's University Of Belfast Cell-permeable peptide
EP1272510B1 (en) 2000-02-07 2007-09-26 Wisconsin Alumni Research Foundation Pharmacologically active antiviral peptides and methods of their use
US7432045B2 (en) 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides

Also Published As

Publication number Publication date
WO2001057072A3 (en) 2002-10-31
AU3670001A (en) 2001-08-14
CA2399676C (en) 2010-04-06
US20120157376A1 (en) 2012-06-21
US8748565B2 (en) 2014-06-10
US7371809B2 (en) 2008-05-13
DE60130641D1 (de) 2007-11-08
US20090253624A1 (en) 2009-10-08
EP1272510A2 (en) 2003-01-08
EP1272510B1 (en) 2007-09-26
DE60130641T2 (de) 2008-06-26
AU784264B2 (en) 2006-03-02
ATE374208T1 (de) 2007-10-15
US8748566B2 (en) 2014-06-10
WO2001057072A2 (en) 2001-08-09
ES2293977T3 (es) 2008-04-01
JP2003522185A (ja) 2003-07-22
CA2399676A1 (en) 2001-08-09
US20050130884A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
US8748566B2 (en) Pharmacologically active antiviral peptides and methods of use
US10308685B2 (en) Inhibitory peptides of viral infection
JP2724711B2 (ja) 医薬品生成物
US4800081A (en) Methods and compositions for treating viral infections
Akkarawongsa et al. Corneal toxicity of cell-penetrating peptides that inhibit herpes simplex virus entry
US4663317A (en) Methods and compositions for treating viral infections
US4849412A (en) Methods and compositions for treating viral infections
Hayashi et al. Yucca leaf protein (YLP) stops the protein synthesis in HSV-infected cells and inhibits virus replication
US7432045B2 (en) Method of inhibiting influenza infection with antiviral peptides
JP2938916B2 (ja) ヘルペスウィルスの増殖阻害および潜伏感染後の再発阻止剤
JP2877908B2 (ja) 抗ヘルペスペンタペプチド類
AU2006202024B2 (en) Pharmacologically active antiviral peptides and methods of their use
EP1862471A2 (en) Pharmacologically active antiviral peptides and methods of their use
JP7333538B2 (ja) 抗ウイルス性ペプチドおよびその利用
SK29795A3 (en) Inhibition of retrovirus infection
CN100390183C (zh) 稀土杂多化合物抗病毒药物
JP2001072597A (ja) 抗ヘルペスウイルス剤
US4782065A (en) Methods and compositions for treating viral infections
JP4535713B2 (ja) 抗ヒトサイトメガロウイルス剤
CN116535468A (zh) 胡蜂毒液多肽Protonectarina-MP及其抗病毒应用
Galasso Promises to keep: clinical use of antiviral drugs
CN118267451A (zh) 一种基于病毒阻断剂的鼻腔清洗喷雾剂及其用途
CN118267450A (zh) 一种抗病毒胡蜂多肽及其应用
JPH0688904B2 (ja) ウイルスに対する増殖抑制剤
Varadinova et al. In vitro Antiherpes Activity of Oxadin®

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110228

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110922

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111221

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees